Search research articles
Contact Us
Filters
Showing results (71-80 of 210) with videos related to
Page
of 21
Sort By:
Cytotherapy
|
September 10, 2025
Overcoming barriers to referral for CAR T-cell therapy in patients with non-Hodgkin aggressive B-cell lymphomas: A Delphi consensus
Stefano Luminari, Annalisa Chiappella, Alice Di Rocco, et al.
Hemasphere
|
April 20, 2026
Dynamics of complete responses (CRs) in patients with relapsed or refractory follicular lymphoma (R/R FL) treated with odronextamab in the ELM-2 study
Stefano Luminari, Ana Jiménez-Ubieto, Geoffrey Chong, et al.
Leukemia & Lymphoma
|
December 30, 2009
Long term outcome of patients with localized aggressive non-Hodgkin lymphoma treated with PROMECE-CYTABOM plus involved-field radiation therapy: a study by the Gruppo Italiano Studio Linfomi
Donato Mannina, Stefano Luminari, Alessandra Dondi, et al.
Haematologica
|
November 13, 2008
High-dose therapy and autologous stem cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy: long-term results
Angelo Michele Carella, Monica Bellei, Pauline Brice, et al.
Leukemia & Lymphoma
|
September 18, 2015
A phase II study of bendamustine in combination with rituximab as initial treatment for patients with indolent non-follicular non-Hodgkin lymphoma
Stefano Luminari, Maria Goldaniga, Marina Cesaretti, et al.
British Journal of Haematology
|
March 11, 2014
Bendamustine for Hodgkin lymphoma patients failing autologous or autologous and allogeneic stem cell transplantation: a retrospective study of the Fondazione Italiana Linfomi
Antonella Anastasia, Carmelo Carlo-Stella, Paolo Corradini, et al.
Leukemia & Lymphoma
|
January 30, 2014
Perception of hepatitis B virus infection reactivation-related issues among specialists managing hematologic malignancies: result of an Italian survey
Massimo Marignani, Alfredo Marzano, Paola Begini, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 14, 2003
High-dose therapy and autologous stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy
Massimo Federico, Monica Bellei, Pauline Brice, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 26, 2023
Long-Term Follow-Up of the Response-Adjusted Therapy for Advanced Hodgkin Lymphoma Trial
Stefano Luminari, Alexander Fossa, Judith Trotman, et al.
British Journal of Haematology
|
November 28, 2018
Phase II trial to investigate efficacy and safety of bendamustine, dexamethasone and thalidomide in relapsed or refractory multiple myeloma patients after treatment with lenalidomide and bortezomib
Michael Mian, Norbert Pescosta, Stefania Badiali, et al.
Page
of 21
Search research articles
Search
Showing results (71-80 of 210) with videos related to
Sort By:
Page
of 21
Cytotherapy
|
September 10, 2025
Overcoming barriers to referral for CAR T-cell therapy in patients with non-Hodgkin aggressive B-cell lymphomas: A Delphi consensus
Stefano Luminari, Annalisa Chiappella, Alice Di Rocco, et al.
Hemasphere
|
April 20, 2026
Dynamics of complete responses (CRs) in patients with relapsed or refractory follicular lymphoma (R/R FL) treated with odronextamab in the ELM-2 study
Stefano Luminari, Ana Jiménez-Ubieto, Geoffrey Chong, et al.
Leukemia & Lymphoma
|
December 30, 2009
Long term outcome of patients with localized aggressive non-Hodgkin lymphoma treated with PROMECE-CYTABOM plus involved-field radiation therapy: a study by the Gruppo Italiano Studio Linfomi
Donato Mannina, Stefano Luminari, Alessandra Dondi, et al.
Haematologica
|
November 13, 2008
High-dose therapy and autologous stem cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy: long-term results
Angelo Michele Carella, Monica Bellei, Pauline Brice, et al.
Leukemia & Lymphoma
|
September 18, 2015
A phase II study of bendamustine in combination with rituximab as initial treatment for patients with indolent non-follicular non-Hodgkin lymphoma
Stefano Luminari, Maria Goldaniga, Marina Cesaretti, et al.
British Journal of Haematology
|
March 11, 2014
Bendamustine for Hodgkin lymphoma patients failing autologous or autologous and allogeneic stem cell transplantation: a retrospective study of the Fondazione Italiana Linfomi
Antonella Anastasia, Carmelo Carlo-Stella, Paolo Corradini, et al.
Leukemia & Lymphoma
|
January 30, 2014
Perception of hepatitis B virus infection reactivation-related issues among specialists managing hematologic malignancies: result of an Italian survey
Massimo Marignani, Alfredo Marzano, Paola Begini, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 14, 2003
High-dose therapy and autologous stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy
Massimo Federico, Monica Bellei, Pauline Brice, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 26, 2023
Long-Term Follow-Up of the Response-Adjusted Therapy for Advanced Hodgkin Lymphoma Trial
Stefano Luminari, Alexander Fossa, Judith Trotman, et al.
British Journal of Haematology
|
November 28, 2018
Phase II trial to investigate efficacy and safety of bendamustine, dexamethasone and thalidomide in relapsed or refractory multiple myeloma patients after treatment with lenalidomide and bortezomib
Michael Mian, Norbert Pescosta, Stefania Badiali, et al.
Page
of 21